BackSunshine Biopharma- Warrants (15/02/2027) Overview

Sunshine Biopharma- Warrants (15/02/2027) Current Cash

Sunshine Biopharma- Warrants (15/02/2027)'s current cash is $6.9M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$6.91M
14.91% YoYΔ $-1.21M vs prior year quarter

Peer average

Loading

Sunshine Biopharma- Warrants (15/02/2027) Current Cash History

Loading

Sunshine Biopharma- Warrants (15/02/2027) vs. peers: Current Cash Comparison

Loading

Sunshine Biopharma- Warrants (15/02/2027) Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sunshine Biopharma- Warrants (15/02/2027) (SBFMW) FAQ

Sunshine Biopharma- Warrants (15/02/2027) (SBFMW) currently reports a current cash of $6.9M as of March 2026. That compares with $8.1M in the prior-year period — down 14.9% year over year. Use the charts on this page to explore Sunshine Biopharma- Warrants (15/02/2027)'s current cash history and peer comparisons.

Sunshine Biopharma- Warrants (15/02/2027)'s current cash decreased from $8.1M to $6.9M — a 14.9% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sunshine Biopharma- Warrants (15/02/2027) reported $6.9M in current cash as of March 2026. That compares with $8.1M in the prior-year period — down 14.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $6.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sunshine Biopharma- Warrants (15/02/2027), and consider following SBFMW for alerts when major investors trade the stock.

Sunshine Biopharma- Warrants (15/02/2027) is classified in the Healthcare sector. On current cash, it currently shows $6.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SBFMW with unrelated industries.